|
|
Volumn 299, Issue 8, 2008, Pages 885-887
|
|
Controversies surround heart drug study: Questions about Vytorin and trial sponsors' conduct
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EZETIMIBE;
EZETIMIBE PLUS SIMVASTATIN;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
SIMVASTATIN;
ANTILIPEMIC AGENT;
AZETIDINE DERIVATIVE;
EZETIMIBE SIMVASTATIN COMBINATION;
EZETIMIBE-SIMVASTATIN COMBINATION;
UNCLASSIFIED DRUG;
ARTERY INTIMA PROLIFERATION;
ATHEROSCLEROSIS;
CARDIOVASCULAR RISK;
CAROTID ARTERY;
CLINICAL TRIAL;
DISEASE MARKER;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MECHANISM;
DRUG RESEARCH;
DRUG SAFETY;
FAMILIAL HYPERCHOLESTEROLEMIA;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MONOTHERAPY;
PRIORITY JOURNAL;
SHORT SURVEY;
DRUG COMBINATION;
LEGAL LIABILITY;
NOTE;
RANDOMIZED CONTROLLED TRIAL;
UNITED STATES;
ANTILIPEMIC AGENTS;
AZETIDINES;
DRUG APPROVAL;
DRUG COMBINATIONS;
DRUG INDUSTRY;
HUMANS;
LIABILITY, LEGAL;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
SIMVASTATIN;
UNITED STATES;
|
|
EID: 40349089476
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.299.8.885 Document Type: Short Survey |
|
Times cited : (21)
|
|
References (0)
|